rs137854592
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000397.4(CYBB):c.676C>T(p.Arg226Ter) variant causes a stop gained, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000895 in 111,757 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000397.4 stop_gained, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CYBB | NM_000397.4 | c.676C>T | p.Arg226Ter | stop_gained, splice_region_variant | 7/13 | ENST00000378588.5 | |
CYBB | XM_047441855.1 | c.370C>T | p.Arg124Ter | stop_gained, splice_region_variant | 6/12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CYBB | ENST00000378588.5 | c.676C>T | p.Arg226Ter | stop_gained, splice_region_variant | 7/13 | 1 | NM_000397.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00000895 AC: 1AN: 111757Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 34033
GnomAD3 exomes AF: 0.00000578 AC: 1AN: 173035Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 58995
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1091611Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 358473
GnomAD4 genome ? AF: 0.00000895 AC: 1AN: 111757Hom.: 0 Cov.: 23 AF XY: 0.00 AC XY: 0AN XY: 34033
ClinVar
Submissions by phenotype
Granulomatous disease, chronic, X-linked Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 29, 2016 | Variant summary: The CYBB c.676C>T (p.Arg226X) variant results in a premature termination codon, predicted to cause a truncated or absent CYBB protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant of interest was not observed in controls (ExAC, 1000 Gs or ESP) and has been reported in multiple affected individuals. In addition, a reputable database cites the variant as "pathogenic." Therefore, the variant of interest has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 19, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center of Genomic medicine, Geneva, University Hospital of Geneva | Jun 09, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 29, 2023 | This sequence change creates a premature translational stop signal (p.Arg226*) in the CYBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CYBB are known to be pathogenic (PMID: 9585602, 20729109). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with X-linked chronic granulomatous disease (PMID: 1347621, 18546332, 20729109, 23859418, 29560547). ClinVar contains an entry for this variant (Variation ID: 10929). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 02, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 22, 2021 | Published functional studies demonstrated lack of protein expression in neutrophil cells of affected individuals with the p.(R226X) variant (Sun et al., 2012); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 8634410, 1347621, 23859418, 25525159, 10914676, 16569599, 11162142, 9585602, 18546332, 20729109, 24999735, 28153086, 28577521, 28006982, 29560547, 21190454, 30290665, 30470980, 7949143, 31522453, 32040803, 32954498, 34134972, 33717137, 22924737) - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 10, 2017 | The CYBB c.676C>T, p.Arg226Ter variant is reported in the medical literature in multiple individuals diagnosed with X-linked chronic granulomatous disease (CGD) (Curnette 1992, Roos 1996, Rae 1998, Ishibashi 2000, Heyworth 2001, Gerard 2001, von Goessel 2006, Kannengiesser 2008), and listed as pathogenic in CYBB variant database (CYBBbase) (Roos 2010). Functional characterization indicates that the variant leads to the loss of NAPDH-oxidase activity (Curnette 1992, von Goessel 2006, Kannengiesser 2008), resulting in functionally defective neurophils (Kannengiesser 2008). The variant is listed in the ClinVar database (Variation ID: 10929) and the dbSNP variant database (rs137854592). It is not observed in the general population databases, such as the 1000 Genomes Project, the Exome Variant Server, and the Exome Aggregation Consortium (ExAC). The variant introduces a premature termination codon and is predicted to result in a truncated protein or mRNA subject to non-sense mediated decay. Based on the above information, this variant is classified as pathogenic. References: Curnutte J et al. Studying X inactivation. Lancet. 1992 339(8795):749. Gerard B et al. Characterization of 11 novel mutations in the X-linked chronic granulomatous disease (CYBB gene). Hum Mutat. 2001 18(2):163. Heyworth P et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis. 2001 27(1):16-26. Ishibashi F et al. Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency. Hum Genet. 2000 106(5):473-81. Kannengiesser C et al. Molecular epidemiology of chronic granulomatous disease in a series of 80 kindreds: identification of 31 novel mutations. Hum Mutat. 2008 29(9):E132-49. Rae J et al. X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet.1998 62(6):1320-31. Roos D et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010 45(3):246-65. Roos D et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood.1996 87(5):1663-81. Von Goessel H et al. Characterization of 17 new cases of X-linked chronic granulomatous disease with seven novel mutations in the CYBB gene. Exp Hematol. 2006 34(4):528-35. - |
Chronic granulomatous disease Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 17, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at